Sensus Healthcare, INC 8-K filings

Sensus Healthcare has entered into a new $15 million revolving credit facility with City National Bank of Florida to support working capital needs.

Sensus Healthcare, Inc. reported on its Annual Meeting of Stockholders held on May 29, 2026, where directors were elected and executive compensation was approved.

Sensus Healthcare announced its fourth quarter and full-year 2025 financial results, reporting significant losses but expressing optimism for 2026 profitability driven by new dedicated CPT codes for SRT.

Sensus Healthcare, Inc. announced the appointment of Carr, Riggs & Ingram, LLC as its new independent registered public accounting firm, replacing Berkowitz Pollack Brant Advisors + CPAs, LLP.

Sensus Healthcare, Inc. announced the appointment of Larry Biscotti, President of Imaging for U.S. and Canada at GE HealthCare, to its Board of Directors, effective immediately.

Sensus Healthcare, Inc. announced the appointment of Eric Sachetta as a Class II director, filling a vacancy and joining the Audit Committee.

Sensus Healthcare reported a net loss of $0.9 million in Q3 2025, a significant decline from prior year income, despite new CMS coding validating SRT for non-melanoma skin cancer.

Sensus Healthcare reported a net loss of $1.0 million on revenues of $7.3 million for Q2 2025, impacted by lower unit sales and proposed reimbursement changes.

Sensus Healthcare, Inc. announced that its stockholders approved all proposals at the Annual Meeting held on May 27, 2025, including the re-election of a director, amendment of the 2017 Incentive Plan, advisory approval of executive compensation, and ratification of the independent auditor.

Sensus Healthcare announces Q1 2025 financial results with a revenue decrease but anticipates profitability for the rest of the year.

Sensus Healthcare announces the resumption of its $3 million share repurchase program, signaling confidence in growth prospects and commitment to enhancing shareholder value.

Sensus Healthcare announces strong Q4 and full-year 2024 financial results, highlighted by record SRT system shipments and continued profitability.

Sensus Healthcare's third quarter 2024 revenue more than doubled compared to the same period last year, reaching $8.8 million, with adjusted EBITDA also turning positive.

Sensus Healthcare's third quarter 2024 financial results show a significant increase in revenue, more than doubling compared to the same period last year, and a return to profitability.

Sensus Healthcare has changed its independent auditor from Marcum LLP to Berkowitz Pollack Brant Advisors + CPAs, LLP due to independence concerns arising from Marcum's merger with CBIZ Inc.

Sensus Healthcare's second quarter 2024 revenue more than doubled compared to the same period last year, reaching $9.2 million, with adjusted EBITDA also turning positive.

Sensus Healthcare's annual meeting saw the re-election of two directors, approval of an amendment to the company's charter, and ratification of the auditor appointment.

Sensus Healthcare, Inc. announced the immediate resignation of Dr. John Heinrich from its Board of Directors on May 30, 2024.

Sensus Healthcare announced a significant increase in revenue and a return to profitability in the first quarter of 2024, driven by strong sales of its SRT systems.

Sensus Healthcare announced its fourth quarter and full year 2023 financial results, highlighting a significant revenue increase in Q4 and the introduction of a recurring revenue model.

Sensus Healthcare director, Samuel O'Rear, will not seek re-election at the company's 2024 annual meeting.

Sensus Healthcare has appointed Michael Sardano, son of the CEO, to its Board of Directors, effective February 1, 2024.